

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Commentors on the draft scope and contributors to the scoping workshop identified the following potential equality issues:

- People with lower socioeconomic status may derive greater benefit from teplizumab as they tend to have lower participation in structured diabetes education and reduced attendance at specialist diabetes services compared to people with higher socioeconomic status. However, these people may find it harder to access treatment given that it is provided in a specialised hospital setting.
- First-degree relatives of people with type 1 diabetes are more likely to have been screened for pancreatic islet autoantibodies – a pre-requisite for treatment with teplizumab. Without a national screening programme, teplizumab will only be available to those with an individual knowledge of early-stage type 1 diabetes. People excluded from treatment may include those from marginalised groups.
- People with a mental health condition may find engaging with insulin therapy difficult.
- Stakeholders noted that teplizumab could be more cost effective in people younger than 18, and suggested that subgroups based on age could be considered.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

If relevant, the potential equality issues will be considered by the committee during decision making.

If evidence allows, consideration may be given to subgroups based on age. If consideration is given to these subgroups, the committee will consider any equalities implications of its considerations.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

The scope notes that subgroups based on age may be considered, and if so that equalities implications should be considered.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director (name): Ian Watson

Date: 23/09/2024